656 related articles for article (PubMed ID: 31837940)
21. Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
Liu H; Ye T; Yang X; Lv P; Wu X; Zhou H; Lu H; Tang K; Ye Z
Dis Markers; 2020; 2020():8375348. PubMed ID: 32685057
[TBL] [Abstract][Full Text] [Related]
22. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
23. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
24. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract][Full Text] [Related]
25. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract][Full Text] [Related]
26. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
[No Abstract] [Full Text] [Related]
27. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
[TBL] [Abstract][Full Text] [Related]
28. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
[No Abstract] [Full Text] [Related]
29. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
30. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
[TBL] [Abstract][Full Text] [Related]
31. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
32. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
[TBL] [Abstract][Full Text] [Related]
34. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
35. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
36. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
37. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
[TBL] [Abstract][Full Text] [Related]
40. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.
Alessandrino F; Gujrathi R; Nassar AH; Alzaghal A; Ravi A; McGregor B; Sonpavde G; Shinagare AB
Eur Urol Oncol; 2020 Oct; 3(5):680-686. PubMed ID: 31412003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
